Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00404573 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 375
- Enrollment target
NCT00404573 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 375 participants.
The verdict
NCT00404573, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 375 participants
- Enrollment target
Study Summary
This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three treatment groups--one of two doses of RGH-188 or placebo
Interventions
- DRUG RGH-188
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 375 participants |
| Start Date | 2006-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00404573
The ClinicalTrials.gov registry entry for NCT00404573 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RGH-188 is the first listed.
NCT00404573 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00404573 about?
NCT00404573 is a clinical study titled "Study Evaluating RGH-188 in the Treatment of Patients With Schizophrenia". This is a study designed to evalute the safety and efficacy of RGH-188 in the treatment of acute schizophrenia. This study will be 10 weeks in duration; 6 weeks double-blind treatment, and 4 weeks safety follow-up. All patients meeting the eligibility criteria will be randomized to one of the three ...
What is the current status of trial NCT00404573?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 375 participants. The study started on 2006-11.
What interventions are being tested in trial NCT00404573?
The interventions under investigation include: RGH-188 (DRUG).
Who is sponsoring clinical trial NCT00404573?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.